#Pfizer
-
China in talks with Pfizer for generic COVID drug
-
Pfizer to invest more than $2.5 bln to expand European manufacturing
-
Pfizer/BioNTech's updated COVID shot shows strong response against BQ.1.1
-
Moderna sues Pfizer/BioNTech for patent infringement over COVID vaccine
-
Pfizer's COVID-19 vaccine 73 pct effective in kids under 5 years
-
Pfizer to boost pipeline with $5.4 billion Global Blood Therapeutics buy
-
Pfizer signs new $3.2 billion COVID vaccine deal with U.S. government
-
Pfizer to buy 8.1 percent stake in French vaccines company Valneva
-
U.S. FDA authorizes Moderna, Pfizer-BioNTech COVID-19 vaccines for kids down to 6 months of age
-
U.S. FDA says Pfizer COVID-19 vaccine effective in children aged under 5
-
Above 1 mln get Pfizer COVID -19 vaccine in Kazakhstan
-
U.S. doctors reconsider Pfizer's Paxlovid for lower-risk COVID patients
-
Pfizer to sell all its patented drugs at nonprofit price in low-income countries
-
Pfizer says COVID shot 80 percent effective in young kids
-
Over 800,000 teens immunized with Pfizer vaccine in Kazakhstan
-
Kazakhstan to purchase 500,000 doses of Pfizer vaccine for revaccination
-
U.S. FDA authorizes Pfizer's COVID booster shot for young children
-
BioNTech posts tripled Q1 vaccine sales but still flags full-year decline
-
Georgia gets first batch of Covid-19 pills Paxlovid
-
Pfizer to provide 10 mln courses of COVID pill to developing countries -the Global Fund
-
US Pfizer's Azerbaijani office announces its liquidation
-
Pfizer jabs for children aged 5-12 to arrive in Georgia in Q2
-
China grants conditional approval for Pfizer's oral COVID-19 drug
-
Pfizer's COVID cash pile opens opportunities for deals
